HealthCare Journey for Multiple Sclerosis
  • About Us
  • Home
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Seminar Registration
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey

Welcome to the Virtual MS Center!

Ask any question you want about Multiple Sclerosis and one of our experts will answer it as soon as possible.
CLICK HERE TO ASK YOUR QUESTION!

Rituxan and Multiple Sclerosis

2/3/2014

 
Question from an MS Patient: 
Is Rituxan an effective treatment for SPMS? What are the benefits or disadvantages? i.e. pros & cons etc. Are there any life-threatening side effects? Would you consider this is a good drug to treat SPMS long term? Do you feel the drug can cause complications-manifest other diseases or illnesses? Are there any results from clinical trials conducted using Rituxan published?

Rituxan (Rituximab) is a chimeric monoclonal antibody that is currently approved for the treatment of two forms of cancer (CD20 positive Non Hodgkin’s Lymphoma (NHL) and chronic lymphocytic leukemia (CLL)) and two immune medicated disorders (moderate to severe rheumatoid arthritis and Wegener’s granulomatosis). It was first approved in 1997 and has been widely used off label to treat a number of rare immune medicated conditions, including neuromyelitis optics (NMO), often with dramatic success. In fact is it currently considered the first line treatment for NMO in many centers around the world. It binds to a protein expressed on the surface of B Cells called CD20 and causes complement mediated lysis of these cells lasting for variable periods of time depending on the dose administered. The mechanism of action in MS is unclear; B cells clearly play a role in the inflammatory response in MS and their elimination seems to benefit many patients. What is unknown is the exact role played by the B cell; for instance some believe the B cell only becomes a problem in MS when co-infected with Epstein Barr Virus.  

Studies of Rituximab in the treatment of relapsing or progressive forms of MS have been few, yet it remains a key treatment option by many MS specialists for certain situations; namely, as an induction therapy for patients with an aggressive onset to their condition, as ongoing treatment in relapsing patients not responsive to other therapies including tysabri or in patients rapidly transitioning to secondary progressive MS despite other available treatment options.  

Why would a drug not even approved by the FDA be considered such an important treatment option by MS specialists? First, those studies that have been done in relapsing forms of MS demonstrate rather dramatic benefits that persist for 6 to 12 months after treatment. MS specialists using the drug in practice report similar benefits in their patients. Studies in progressive forms of MS have reported mixed results which can be expected given the challenges of treating MS at this stage of the disease.  The large phase III study by Genentech in primary progressive MS was a negative study when the entire study population was considered in the analysis. When considering only those patients under the age of 51, those patients with gadolinium enhancing lesions at the beginning of the study or patients with both features, rituximab given every 6 months for 4 courses of treatment significant reduced the rate of sustained disability progression.  A small retrospective analysis of 25 secondary progressive MS patients treated with rituximab every 6 months at the University of Massachusetts in Worcester reported that 84% of patients stabilized or improved while on treatment.

Rituximab is generally safe in most MS patients. The most common side effects are caused by infusion reactions which decrease over time and can be further decreased by administering corticosteroids prior to the infusion. There is also a slight increase in serious infections, though these are treatable. Progressive Multifocal Leukoencephalopathy (PML) has been reported but does not appear as frequently as in Tysabri treated patients. What is unknown are the long term consequences of treatment with Rituximab and the most appropriate dose and dosing interval. Most current dosing regimens are based on the very high doses used to treat cancers, yet we were able to achieve a very good response in relapsing patients given 1/20th of this dose (100 mg) every 6 months for over 3 years of continuous treatment.

Further studies of rituximab are not likely to occur since there is no further patent protection. There are several other monoclonal antibodies in MS clinical trials that target CD20 and delete B cells including ocrelizumab and ofatumumab. Whether these newer treatments offer improvements in safety or efficacy in comparison to rituximab is unclear at this time.

--Dr. Kinkel

PLEASE NOTE:  The medical information on this site is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information does not create any patient-physician relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.


Catherine
2/4/2014 09:44:13 am

Thank you Dr. Kinkel for this valuable information. The answers that you have provided to my questions were in-depth, clear and comprehensive.

Aditya
8/24/2019 11:28:20 am

Dr. Kinkel: given the risks of PML with Rituximab, is HSCT safer for people with SPMS and positive JC virus ( value being 3.84) ?


Comments are closed.

    RSS Feed

    PLEASE NOTE: This information/opinions on this site should be used as an information source only.  This information does not create any patient-HCP relationship, and should not be used as a substitute for professional diagnosis and treatment.  Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition.
    Read About Our Virtual MS Center Authors

    Archives

    September 2024
    June 2024
    March 2024
    January 2024
    December 2023
    November 2023
    October 2023
    September 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    July 2013
    June 2013

    Categories

    All
    Accessible Housing And Environmental Modifications
    Anxiety
    Balance
    Bowel Problems
    Caregivers
    Cognitive Function
    Compliance
    David Rintell Ed. D.
    Deborah Backus Blogs
    Depression
    Diagnosis
    Diet
    Dizziness
    Dosing
    Dr. Greenberg's Q&A
    Dr. Kinkel's Q&A
    Dr. Miravalle's Q&A
    Dr. Nielsen's Q&A
    Dr. Osborne's Q&A
    Exercise
    Experimental Treatments
    Eye Surgery
    Fatigue
    Fatique
    Flu Shot
    Foot Drop
    Herbs
    Immunosuppression
    JCV
    Lasik Surgery
    Lesions
    Lori Kostich's Q&A
    Lyme Disease
    Medications
    Migraines
    Mobility
    MRI
    MS Hug
    Other Diseases
    Pain
    PML
    PPMS
    Pregnancy
    Relapse
    Safety
    Sarah Wargo's Q&A
    Sexual Dysfunction
    Side Effects
    Smoking
    Spasticity
    Stem Cell Transplantation
    Steroids
    Stress
    Supplements
    Surgery
    Symptoms
    Treatment
    Urination
    Viruses
    Vision
    Vitamin D
    Vitamins
    Weakness


© 2023 HealthCare Journey, LLC. All Rights Reserved.
HealthCare Journey™ is a trademark of HealthCare Journey, LLC
Picture
  • About Us
  • Home
  • Virtual MS Center
    • Q & A for Virtual MS Center
    • Read About Our Virtual MS Center Staff
  • News & Resources
  • Seminar Registration
  • Health & Wellness
  • Blogs
    • Physician Blog >
      • Healthcare Provider Blog
    • Physical Therapy Blog
    • Patient Blog
    • Caregiver Blog
    • Research Blogs >
      • "Ask Dr. Debbie" Research Blog
      • Multiple Perspectives In Multiple Sclerosis Research Blog
  • About MS
    • What is MS?
    • Diagnosis
    • Treatment
    • MS Tips
  • Symptoms
    • Balance and Walking Issues
    • Breathing/Respiratory
    • Bowel Dysfunction
    • Cognitive Dysfunction
    • Crying/Laughing Uncontrollably (PBA)
    • Depression and Anxiety
    • Dizziness/Vertigo
    • Dysphagia
    • Fatigue
    • Foot Drop
    • Hearing or Smell or Taste Changes
    • Heat Sensitivity
    • Leg Weakness
    • Loss of Hand Dexterity and Coordination
    • Memory and Mutliple Sclerosis
    • Migraines
    • Numbness/Tingling/Altered Sensation
    • Nystagmus and Oscillopsia
    • Pain
    • Sexual Dysfunction
    • Sleep Issues
    • Spasticity/Spasms/Cramps
    • Speech/Swallowing
    • Urination/Bowel Problems
    • Vision
  • MS Clinics
  • MS Topics
    • Pregnancy and Infertility
    • Caregivers and Family Members
    • Employment and MS
    • Medical Costs and Insurance
    • Pediatric Multiple Sclerosis
  • Register With Us
  • Terms of Use/Privacy/HIPAA
  • MS HealthCare Journey